Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 27, 2017
Pharmacy Choice - Pharmaceutical News - "Cardiologs ECG Analysis Platform" Receives FDA Clearance - July 27, 2017

Pharmacy News Article

 7/17/17 - "Cardiologs ECG Analysis Platform" Receives FDA Clearance

By a News Reporter-Staff News Editor at Cardiovascular Week Cardiologs Technologies SAS announced that it has received FDA clearance of its Cardiologs ECG Analysis Platform, a cloud-based cardiac monitoring-analysis web service powered by artificial intelligence (AI). Cardiologs aids physicians in screening for atrial fibrillation (AFib) and other arrhythmias using long-term ambulatory ECG monitoring recordings. The Cardiologs system is also CE-marked in Europe (see also Cardiologs Technologies SAS).

Atrial fibrillation (AFib) is the most common human arrhythmia, affecting about 33 million patients worldwide. AFib is a growing problem in cardiovascular disease and is associated with an increased risk of severe stroke, heart failure, and death. AFib is often asymptomatic, with stroke as the first manifestation. Indeed, recent stroke registries indicate that AFib is associated with one-third of all ischemic strokes.

"It is intuitive that screening for AFib and subsequent anticoagulant treatment should reduce the stroke burden, which is the basis of guideline recommendations to screen for AFib in persons over the age of 65," said Dr. Arnaud Rosier, cardiac electrophysiologist at the Hopital Jacques Cartier, Massy. "Unfortunately, current R-R interval based methods to detect AFib are characterized by an inferior Positive Predictive Value (PPV) of under 59%, leading to misdiagnoses, mostly false positives, that add significant cost to the healthcare system while burdening healthcare resources and placing unnecessary stress on misdiagnosed patients or putting undiagnosed patients in harm's way."

"Cardiologs is a game-changer for arrhythmia screening," added Yann Fleureau, co-founder and CEO of Cardiologs Technologies. "A cardiologist recovers a digital ECG from any compatible cardiac monitoring device-such as a Holter monitor, smartwatch, ECG patch or even a connected t-shirt-then uploads it to the Cardiologs cloud and is able to immediately leverage our technology to identify relevant events. It is especially powerful for long-term recordings that used to require a very laborious manual analysis process.

"Our Cardiologs team has trained a neural network using more than 500,000 recordings, and this training dataset keeps growing," said Fleureau. "The result is that Cardiologs is designed to recognize patterns in a cardiac signal for fast and precise analysis of arrhythmias such as AFib in a similar intuitive manner as expert cardiologists. We especially bring the P-wave detection (atrial activity) to a whole new level, which explains our radically better PPV," said Fleureau. Scientific Validation of Cardiologs. When defining the reliability of diagnosing AFib and other arrhythmias, the term Positive Predictive Value (PPV) refers to the percentage of true positive cases among total cases detected. Conventional "state-of-the-art" PPV for detecting AFib is less than 59%1. The PPV for Cardiologs' detection of AFib was 91%2 included in the cleared FDA submission. In addition, also as included in the cleared FDA submission, Cardiologs' sensitivity for detecting AFib was reported to be 97%3 (the percentage of positive cases truly identified) and was superior to "state-of-the-art" conventional methods of detecting AFib and other arrhythmias. Cardiologs' study results have been published in the European Journal of Preventive Cardiology (2016, Vol. 23(2S 41-55). The study's investigators concluded: "This (Cardiologs) method may be more reliable and accurate than previous methods in the diagnosis of AFib on long-duration ambulatory ECG and other monitoring devices." About Cardiologs Technologies SASHeadquartered in Paris, Cardiologs Technologies is a privately held company offering the "Cardiologs ECG Analysis" platform to aid cardiologists in screening for arrhythmias such as AFib using long-duration ambulatory ECG monitoring recordings. 1 Source: European Journal of Preventive Cardiology (2016, Vol. 23(2S 41-55).2 Duration PPV results from testing following the recognized consensus standards ANSI/AAMI EC57:2012 and IEC 60601-2-47:2012 on MIT-BIH database.3 Duration Sensitivity results from testing following the recognized consensus standards ANSI/AAMI EC57:2012 and IEC 60601-2-47:2012 on MIT-BIH database. View source version on businesswire.com: http://www.businesswire.com/news/home/20170705006011/en/

Keywords for this news article include: Heart Disease, Atrial Fibrillation, Cardiac Arrhythmias, Risk and Prevention, Diagnostics and Screening, Cardiologs Technologies SAS, Heart Disorders and Diseases.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC



(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jul 27: On the Move: A Comprehensive Review of Osteoarthritis, Gout & Rheumatoid Arthritis
Jul 31: Obesity Management: Overview of Pharmacotherapy
Aug 01: Treatment of Depression and Anxiety in Older Adults
Aug 02: Adverse Drug Events: Risk Reduction & Documentation
Aug 03: Medication Use During Pregnancy & Lactation
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415